Androgen News and Research

RSS

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

FDA issues a Complete Response Letter for GTx' toremifene NDA

GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).

2 Nov 2009

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop.

30 Oct 2009

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways.

14 Oct 2009

Androgen deficiency linked to diabetes and cardiovascular diseases

Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD). These findings appear in the September/October issue of the Journal of Andrology.

25 Sep 2009

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

24 Sep 2009

Hormone therapy for treating prostate cancer is linked to heart problems

Berlin, Germany: New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.

22 Sep 2009

Cryosurgery: Primary treatment option for prostate cancer

After years of innovation and intensive research, a team of Binghamton University (BU) researchers working with Cell Preservation Services, Inc., Owego, NY has broken extraordinary new ground in the recognition of cryosurgery as a primary treatment option for prostate cancer.

16 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone. New findings by researchers at Fred Hutchinson Cancer Research Center, published online Aug. 27 in Science, suggest that in nematode worms, at least, this does not hold true.

28 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

Promising new treatment target for Kennedy's disease

New research with transgenic mice reveals that a therapy directed at the muscle significantly improves disease symptoms of a genetic disorder characterized by destruction of the neurons that control movement. The study, published by Cell Press in the August 13th issue of the journal Neuron, highlights a promising new treatment for this currently incurable and nontreatable neurodegenerative disorder.

12 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009